Autolus Therapeutics plc (6A3A) — Cash Flow-to-Debt Ratio
Autolus Therapeutics plc (6A3A) has a Cash Flow-to-Debt Ratio of -0.16x as of December 2025, meaning its operating cash flow of €-67.32 Million could theoretically repay 0% of its total liabilities (€410.94 Million) in one year. See Autolus Therapeutics plc (6A3A) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Autolus Therapeutics plc Cash Flow-to-Debt Ratio (2017–2025)
Historical debt coverage capacity for Autolus Therapeutics plc across 9 annual periods. Also explore net asset momentum of Autolus Therapeutics plc to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Autolus Therapeutics plc (2017–2025)
Year-by-year debt coverage analysis for Autolus Therapeutics plc. For market capitalisation and broader financial context, see 6A3A stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.69x | €-283.57 Million | €410.94 Million | ▼ -18.9% |
| 2024 | -0.58x | €-206.27 Million | €355.40 Million | ▼ -5.2% |
| 2023 | -0.55x | €-145.59 Million | €263.91 Million | ▲ +5.9% |
| 2022 | -0.59x | €-112.31 Million | €191.60 Million | ▲ +54.1% |
| 2021 | -1.28x | €-117.86 Million | €92.24 Million | ▲ +8.6% |
| 2020 | -1.40x | €-117.76 Million | €84.20 Million | ▲ +32.9% |
| 2019 | -2.08x | €-101.48 Million | €48.69 Million | ▲ +13.1% |
| 2018 | -2.40x | €-42.52 Million | €17.74 Million | ▲ +11.2% |
| 2017 | -2.70x | €-16.36 Million | €6.06 Million | — |